Elizabeth Yeu Lin Sells 4,601 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Elizabeth Lin sold 4,601 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $73.86, for a total transaction of $339,829.86. Following the completion of the sale, the insider owned 18,707 shares of the company’s stock, valued at $1,381,699.02. This trade represents a 19.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Elizabeth Yeu Lin also recently made the following trade(s):

• On Wednesday, September 2nd, Elizabeth Lin sold 1,590 shares of Tarsus Pharmaceuticals stock. The stock was sold at an average price of $80.00, for a total transaction of $127,200.00.
• On Wednesday, September 2nd, Elizabeth Lin sold 5,387 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $80.00, for a total transaction of $430,960.00.

Tarsus Pharmaceuticals Price Performance

TARS stock traded up $0.45 during mid-day trading on Thursday, reaching $83.21. The company’s stock had a trading volume of 733,653 shares, compared to its average volume of 744,913. The stock has a market cap of $3.65 billion, a PE ratio of -76.34 and a beta of 0.54. The company has a current ratio of 3.20, a quick ratio of 3.17 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $48.20 and a fifty-two week high of $85.25. The company’s 50 day moving average is $65.08 and its two-hundred day moving average is $65.59.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.24). The business had revenue of $173.91 million during the quarter, compared to analysts’ expectations of $169.65 million. Tarsus Pharmaceuticals had a negative return on equity of 13.53% and a negative net margin of 7.67%. Equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -2.06 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Guggenheim lowered their price objective on Tarsus Pharmaceuticals from $90.00 to $89.00 and set a “buy” rating on the stock in a research note on Tuesday, July 21st. Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Mizuho reduced their price target on Tarsus Pharmaceuticals from $100.00 to $98.00 and set an “outperform” rating on the stock in a report on Friday, July 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $88.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday, July 9th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tarsus Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $90.50.

Institutional Trading of Tarsus Pharmaceuticals

Several institutional investors have recently made changes to their positions in TARS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Tarsus Pharmaceuticals by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock worth $1,137,000 after acquiring an additional 1,217 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Tarsus Pharmaceuticals by 2.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock worth $3,659,000 after acquiring an additional 1,394 shares during the last quarter. Jane Street Group LLC raised its position in Tarsus Pharmaceuticals by 105.8% in the first quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after purchasing an additional 190,000 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Tarsus Pharmaceuticals by 402.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 140,610 shares of the company’s stock valued at $5,696,000 after purchasing an additional 112,637 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Tarsus Pharmaceuticals by 12.3% in the 2nd quarter. Invesco Ltd. now owns 928,501 shares of the company’s stock valued at $37,614,000 after purchasing an additional 101,978 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.